• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于接受 D2 胃切除术和 S-1 辅助化疗的 II/III 期胃癌患者,肿瘤宏观大小是独立的预后因素。

Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.

机构信息

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama, 241-0815, Japan.

出版信息

Gastric Cancer. 2011 Aug;14(3):274-8. doi: 10.1007/s10120-011-0038-0. Epub 2011 Apr 2.

DOI:10.1007/s10120-011-0038-0
PMID:21461654
Abstract

BACKGROUND

In patients with stage II/III gastric cancer, tumors often recur even after curative D2 gastrectomy followed by adjuvant S-1 chemotherapy. The objective of this retrospective study was to clarify the prognostic factors in these patients that might be useful for future patients.

METHODS

Overall survival (OS) was examined in 82 gastric cancer patients who underwent curative D2 surgery; were diagnosed with stage IIA, IIB, IIIA, IIIB, or IIIC pathologically; and received adjuvant S-1 after surgery between June 2002 and March 2010.

RESULTS

When length of OS was evaluated by the log-rank test, significant differences were observed with regard to macroscopic tumor diameter and the depth of tumor invasion. A macroscopic tumor diameter >70 mm was regarded as a critical point of classification considering survival. Univariate and multivariate Cox's proportional hazard analyses demonstrated that macroscopic tumor diameter was the only significant independent prognosticator. The 5-year survival was 64.9% in patients with a macroscopic tumor diameter <70 mm, and 33.1% in patients with a macroscopic tumor diameter ≥70 mm (P = 0.022).

CONCLUSIONS

The macroscopic tumor diameter was the most important prognostic factor for survival in patients with stage II/III gastric cancer who underwent D2 gastrectomy followed by adjuvant S-1 chemotherapy. Prognostic factors can be affected by adjuvant chemotherapy.

摘要

背景

在 II/III 期胃癌患者中,即使在接受根治性 D2 胃切除术和辅助 S-1 化疗后,肿瘤仍常常复发。本回顾性研究的目的是明确这些患者的预后因素,以便为未来的患者提供参考。

方法

我们对 82 例于 2002 年 6 月至 2010 年 3 月期间接受根治性 D2 手术、病理诊断为 IIA、IIB、IIIA、IIIB 或 IIIC 期、术后接受辅助 S-1 化疗的胃癌患者的总生存期(OS)进行了评估。

结果

通过对数秩检验评估 OS 时,肿瘤的宏观直径和肿瘤侵犯深度存在显著差异。考虑到生存情况,将宏观肿瘤直径>70mm 作为分类的临界点。单因素和多因素 Cox 比例风险分析表明,宏观肿瘤直径是唯一具有显著意义的独立预后因素。宏观肿瘤直径<70mm 的患者 5 年生存率为 64.9%,而宏观肿瘤直径≥70mm 的患者 5 年生存率为 33.1%(P=0.022)。

结论

对于接受 D2 胃切除术和辅助 S-1 化疗的 II/III 期胃癌患者,宏观肿瘤直径是生存的最重要预后因素。辅助化疗可能会影响预后因素。

相似文献

1
Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.对于接受 D2 胃切除术和 S-1 辅助化疗的 II/III 期胃癌患者,肿瘤宏观大小是独立的预后因素。
Gastric Cancer. 2011 Aug;14(3):274-8. doi: 10.1007/s10120-011-0038-0. Epub 2011 Apr 2.
2
Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.接受 D2 胃切除术后 S-1 辅助化疗的 II/III 期胃癌患者腹膜复发的危险因素。
Ann Surg Oncol. 2012 May;19(5):1568-74. doi: 10.1245/s10434-011-2158-5. Epub 2011 Dec 6.
3
Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.胃癌手术后辅助 S-1 化疗后复发的预测因素。
Anticancer Res. 2013 Apr;33(4):1747-51.
4
Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.手术后体重减轻是胃癌患者继续接受 S-1 辅助化疗的独立危险因素。
Ann Surg Oncol. 2013 Jun;20(6):2000-6. doi: 10.1245/s10434-012-2776-6. Epub 2012 Dec 16.
5
Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.S-1 联合奥沙利铂与卡培他滨联合奥沙利铂用于胃癌根治术后辅助化疗的长期疗效比较:一项回顾性、单中心观察性研究。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211039679. doi: 10.1177/15330338211039679.
6
Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.S-1辅助化疗改变II/III期胃癌患者的复发模式和预后因素:一项倾向评分匹配分析
Surgery. 2015 Dec;158(6):1573-80. doi: 10.1016/j.surg.2015.05.017. Epub 2015 Jun 25.
7
Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.在高容量中心治疗的病理分期 II 或 III 期胃癌患者,接受 S-1 单药辅助治疗 1 年的有利长期结果。
Gastric Cancer. 2018 Nov;21(6):1024-1030. doi: 10.1007/s10120-018-0827-9. Epub 2018 Apr 26.
8
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.D2淋巴结清扫术后胃癌患者辅助化疗联合5-氟尿嘧啶/亚叶酸钙与S-1的对比:一项可行性研究
Anticancer Res. 2014 Nov;34(11):6585-91.
9
S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.术后早期应用S-1辅助化疗与进展期胃癌的预后因素存在临床相关性。
Ann Surg Oncol. 2016 Feb;23(2):546-51. doi: 10.1245/s10434-015-4868-6. Epub 2015 Oct 6.
10
Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.瘦体重丢失作为胃癌S-1辅助化疗持续进行的独立危险因素
Ann Surg Oncol. 2015 Aug;22(8):2560-6. doi: 10.1245/s10434-014-4296-z. Epub 2014 Dec 17.

引用本文的文献

1
Impact of histologically poorly cohesive phenotype as a prognostic factor in patients with pStage II/III gastric cancer undergoing adjuvant chemotherapy.组织学上低黏附表型作为接受辅助化疗的Ⅱ/Ⅲ期胃癌患者预后因素的影响
Gastric Cancer. 2025 May;28(3):478-492. doi: 10.1007/s10120-025-01599-6. Epub 2025 Feb 28.
2
Intratumoral microbiome is associated with gastric cancer prognosis and therapy efficacy.肿瘤内微生物组与胃癌预后和治疗效果相关。
Gut Microbes. 2024 Jan-Dec;16(1):2369336. doi: 10.1080/19490976.2024.2369336. Epub 2024 Jun 30.
3
Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer.

本文引用的文献

1
Tumor diameter as a prognostic factor in patients with gastric cancer.肿瘤直径作为胃癌患者的一个预后因素。
Ann Surg Oncol. 2008 Jul;15(7):1959-67. doi: 10.1245/s10434-008-9884-3. Epub 2008 Mar 28.
2
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.使用口服氟嘧啶S-1对胃癌进行辅助化疗。
N Engl J Med. 2007 Nov 1;357(18):1810-20. doi: 10.1056/NEJMoa072252.
3
Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer.宏观肿瘤大小作为胃癌患者的一个简单预后指标。
病理淋巴结阴性T3期胃癌的预后因素及辅助化疗的作用
J Pers Med. 2023 Mar 20;13(3):553. doi: 10.3390/jpm13030553.
4
Potential survival benefits of open over laparoscopic radical gastrectomy for gastric cancer patients beyond three years after surgery: result from multicenter in-depth analysis based on propensity matching.基于倾向评分匹配的多中心深入分析:术后 3 年以上的胃癌患者行开腹根治性胃切除术对比腹腔镜根治性胃切除术的潜在生存获益。
Surg Endosc. 2022 Feb;36(2):1456-1465. doi: 10.1007/s00464-021-08430-0. Epub 2021 Jun 3.
5
Tumor size  ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.肿瘤大小≥50mm 是术后 S-1 单药治疗的 II 期或 III 期胃癌患者的独立预后因素:多机构数据集分析。
World J Surg. 2020 Jan;44(1):194-201. doi: 10.1007/s00268-019-05198-2.
6
Correlation of tumor size and survival in pancreatic cancer.胰腺癌中肿瘤大小与生存情况的相关性。
J Gastrointest Oncol. 2018 Oct;9(5):910-921. doi: 10.21037/jgo.2018.08.06.
7
Clinical significance of primary tumor score determined by tumor depth and size in patients with resectable gastric cancer.肿瘤深度和大小所确定的原发性肿瘤评分在可切除胃癌患者中的临床意义。
Oncotarget. 2018 Jan 4;9(9):8512-8520. doi: 10.18632/oncotarget.23953. eCollection 2018 Feb 2.
8
A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.一种用于可切除胃癌的临床预后评分系统,以预测生存情况及从基于紫杉醇或奥沙利铂的辅助化疗中获益的情况。
Drug Des Devel Ther. 2016 Feb 24;10:241-58. doi: 10.2147/DDDT.S88743. eCollection 2016.
9
Emerging role of S-1 in gastric cancer.S-1在胃癌中的新作用。
Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):219-28. doi: 10.4103/0971-5851.171542.
10
Prognostic Significance of Tumor Size in 2405 Patients With Gastric Cancer: A Retrospective Cohort Study.2405例胃癌患者肿瘤大小的预后意义:一项回顾性队列研究
Medicine (Baltimore). 2015 Dec;94(50):e2288. doi: 10.1097/MD.0000000000002288.
Am J Surg. 2006 Sep;192(3):296-300. doi: 10.1016/j.amjsurg.2006.03.004.
4
Disparities in gastric cancer chemotherapy between the East and West.东西方在胃癌化疗方面的差异。
J Clin Oncol. 2006 May 10;24(14):2188-96. doi: 10.1200/JCO.2006.05.9758.
5
Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses.胃癌胃切除术后的早期和晚期复发。单因素和多因素分析。
Cancer. 2000 Jul 15;89(2):255-61. doi: 10.1002/1097-0142(20000715)89:2<255::aid-cncr8>3.0.co;2-n.
6
Prediction of early and late recurrence after curative resection for gastric carcinoma.
Cancer. 1996 Jun 15;77(12):2445-8. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2445::AID-CNCR5>3.0.CO;2-L.
7
A multifactorial approach for the prognosis of patients with carcinoma of the stomach after curative resection.一种用于胃癌根治性切除术后患者预后评估的多因素方法。
Surg Gynecol Obstet. 1986 Mar;162(3):229-34.